Literature DB >> 1077792

The use of angiotensin-converting enzyme inhibitor in the diagnosis and treatment of hypertension.

H Gavras, H R Brunner, J H Laragh, I Gavras, R A Vukovich.   

Abstract

1. The anti-hypertensive effect of converting enzyme inhibition was evaluated in twenty-three hypertensive patients (seven renovascular, four essential, four malignant, one scleroderma, three chronic renal failure, four primary or idiopathic aldosteronism). 2. In sixteen patients a single injection (1--4 mg/kg) of the inhibitor produced an immediate anti-hypertensive effect, which lasted up to 16 h. In six patients the anti-hypertensive effect of the inhibitor was significantly improved after sodium depletion. 3. Plasma renin activities increased and plasma aldosterone concentrations decreased consistently except in idiopathic aldosteronism. 4. Converting enzyme inhibition provides a direct way of defining the degree of renin-dependency of the hypertension. Accordingly, it can be used diagnostically and for planning appropriate therapy. Therapeutically, it could be advantageous in hypertensive emergencies because of its safety, specificity and capacity to reduce aldosterone secretion.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1077792     DOI: 10.1042/cs048057s

Source DB:  PubMed          Journal:  Clin Sci Mol Med Suppl        ISSN: 0144-4107


  3 in total

Review 1.  New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism.

Authors:  Carlos M Ferrario
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

Review 2.  Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.

Authors:  Carlos M Ferrario; Adam E Mullick
Journal:  Pharmacol Res       Date:  2017-05-29       Impact factor: 7.658

3.  Fate of bradykinin-potentiating peptide 9a after intravenous injection.

Authors:  L C Martin; J W Ryan; G H Fisher; A Chung; M Epstein; J M Stewart
Journal:  Biochem J       Date:  1979-12-15       Impact factor: 3.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.